[The clinical advantage of using three dimensional visualization technology in hepatic surgery].

The three-dimensional body visible system is a further development of the three-dimensional CT reconstruction system. It has a lot of merits over the latter system. Clinical application of the three-dimensional body visible system in liver surgery showed the system to have the following merits: (1) The system can support the Couinaud classification of liver anatomy into two hemilivers, four sectors and eight segments. As the system can rotate the liver to any angle and it has the ability to make part or whole of the liver transparent thus making the internal blood vessels and bile ducts visible. Learning liver anatomy and liver surgery becomes easier. (2)The system can clearly localize liver tumors within the liver segment(s). (3)It can help clinicians to decide and to plan different operations on an individual. (4)By carrying out simulation partial hepatectomy using this system, it can help clinicians to estimate the difficulty and the risks involved in different options of liver resection and finally.(5)The system helps clinicians to identify anomalies in hepatic artery, portal vein, hepatic vein and bile duct, thus making the operation safer. In conclusion, this system significantly improves on the conventional three-dimensional CT reconstruction system. It is especially useful for inexperienced liver surgeons.

Attenuation of Armanni-Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011.

AIMS/HYPOTHESIS: A key morphological feature of diabetic nephropathy is the accumulation and deposition of glycogen in renal tubular cells, known as Armanni-Ebstein lesions. While this observation has been consistently reported for many years, the molecular basis of these lesions remains unclear. METHODS: Using biochemical and histochemical methods, we measured glycogen concentration, glycogen synthase and glycogen phosphorylase enzyme activities, and mRNA expression and protein levels of glycogenin in kidney lysates from control and transgenic (mRen-2)27 rat models of diabetes that had been treated with and without a new anti-fibrotic agent, FT011. RESULTS: Diabetic nephropathy was associated with increased glycogen content, increased glycogen synthase activity and decreased glycogen phosphorylase activity. Glycogenin, the key protein responsible for initiating the synthesis of each glycogen particle, had very high levels in the diabetic kidney together with increased mRNA expression compared with control kidneys. Treatment with FT011 did not change glycogen synthase or glycogen phosphorylase enzyme activities but prevented both glycogenin mRNA synthesis and accumulation of Armanni-Ebstein lesions in the diabetic kidney. CONCLUSIONS/INTERPRETATION: Armanni-Ebstein lesions found in diabetic nephropathy are due to aberrant glycogenin protein levels and mRNA expression, providing an explanation for the increased glycogen concentration found within the diabetic kidney. FT011 treatment in diabetic rats reduced glycogenin levels and, subsequently, renal glycogen concentration.